Literature DB >> 26579878

Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis.

Tatsunori Hanai1, Makoto Shiraki1, Sachiyo Ohnishi1, Tsuneyuki Miyazaki1, Takayasu Ideta1, Takahiro Kochi1, Kenji Imai1, Atsushi Suetsugu1, Koji Takai1,2, Hisataka Moriwaki1, Masahito Shimizu1.   

Abstract

AIM: Sarcopenia impairs the outcome of patients with liver cirrhosis independently of liver function reserves. The aim of this study was to investigate whether the rate of skeletal muscle wasting predicts mortality in cirrhotic patients.
METHODS: This retrospective study evaluated 149 cirrhotic patients who visited our hospital between March 2004 and September 2012. The skeletal muscle cross-sectional area at the level of the third lumbar vertebra was measured by computed tomography, from which the skeletal muscle index was obtained for diagnosis of sarcopenia. The relative change in skeletal muscle area per year (ΔSMA/y) was calculated in each patient. Cox proportional hazards regression analysis was performed to evaluate risk factors for mortality.
RESULTS: Of the 149 cirrhotic patients, 94 (63%) were diagnosed with sarcopenia. The median of ΔSMA/y in all patients was -2.2%. For patients in Child-Pugh class A, B and C, ΔSMA/y was -1.3%, -3.5% and -6.1%, respectively. During a median follow-up period of 39 months (range, 1-110), 45 patients (30%) died. The optimal cut-off value of ΔSMA/y for predicting mortality was -3.1%; the survival rate in patients with ΔSMA/y of -3.1% or less was significantly lower than in patients with ΔSMA/y of more than -3.1% (P < 0.0001). The multivariate Cox proportional hazards model found ΔSMA/y of -3.1% or less to be significantly associated with mortality in cirrhotic patients (hazard ratio = 2.73, 95% confidence interval = 1.43-5.44, P < 0.01).
CONCLUSION: ΔSMA/y is useful for predicting mortality in patients with liver cirrhosis. Management of skeletal muscle may contribute toward improving the outcome of cirrhotic patients.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  Model for End-Stage Liver Disease; mortality; prognosis; sarcopenia; skeletal muscle index

Year:  2016        PMID: 26579878     DOI: 10.1111/hepr.12616

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  47 in total

1.  Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease.

Authors:  Naoki Mizuno; Yuya Seko; Seita Kataoka; Keiichiroh Okuda; Mitsuhiro Furuta; Masashi Takemura; Hiroyoshi Taketani; Tasuku Hara; Atsushi Umemura; Taichiro Nishikawa; Kanji Yamaguchi; Michihisa Moriguchi; Yoshito Itoh
Journal:  J Gastroenterol       Date:  2018-06-14       Impact factor: 7.527

2.  Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.

Authors:  Maiko Namba; Akira Hiramatsu; Hiroshi Aikata; Kenichiro Kodama; Shinsuke Uchikawa; Kazuki Ohya; Kei Morio; Hatsue Fujino; Takashi Nakahara; Eisuke Murakami; Masami Yamauchi; Tomokazu Kawaoka; Masataka Tsuge; Michio Imamura; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2019-09-04       Impact factor: 7.527

3.  Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy.

Authors:  Hiroki Nishikawa; Norihiro Nishijima; Hirayuki Enomoto; Azusa Sakamoto; Akihiro Nasu; Hideyuki Komekado; Takashi Nishimura; Ryuichi Kita; Toru Kimura; Hiroko Iijima; Shuhei Nishiguchi; Yukio Osaki
Journal:  Oncol Lett       Date:  2017-05-31       Impact factor: 2.967

Review 4.  Nutrition and Muscle in Cirrhosis.

Authors:  Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2017-11-08

Review 5.  Hyperammonemia and proteostasis in cirrhosis.

Authors:  Srinivasan Dasarathy; Maria Hatzoglou
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2018-01       Impact factor: 4.294

6.  Muscle wasting and branched-chain amino acid, alpha-ketoglutarate, and ATP depletion in a rat model of liver cirrhosis.

Authors:  Milan Holeček; Melita Vodeničarovová
Journal:  Int J Exp Pathol       Date:  2019-01-13       Impact factor: 1.925

Review 7.  Implications of low muscle mass across the continuum of care: a narrative review.

Authors:  Carla M Prado; Sarah A Purcell; Carolyn Alish; Suzette L Pereira; Nicolaas E Deutz; Daren K Heyland; Bret H Goodpaster; Kelly A Tappenden; Steven B Heymsfield
Journal:  Ann Med       Date:  2018-09-12       Impact factor: 4.709

Review 8.  Sarcopenia from mechanism to diagnosis and treatment in liver disease.

Authors:  Srinivasan Dasarathy; Manuela Merli
Journal:  J Hepatol       Date:  2016-08-08       Impact factor: 25.083

9.  No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma.

Authors:  Issei Saeki; Takahiro Yamasaki; Masaki Maeda; Reo Kawano; Takuro Hisanaga; Takuya Iwamoto; Toshihiko Matsumoto; Isao Hidaka; Tsuyoshi Ishikawa; Taro Takami; Isao Sakaida
Journal:  Liver Cancer       Date:  2018-04-06       Impact factor: 11.740

10.  Excessive alcohol intake and liver fibrosis are associated with skeletal muscle mass reduction in elderly men: the Wakayama study.

Authors:  Shuhei Onishi; Nobuyuki Miyai; Yan Zhang; Toshifumi Oka; Eriko Nogami; Miyoko Utsumi; Mikio Arita
Journal:  Aging Clin Exp Res       Date:  2021-06-12       Impact factor: 3.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.